TABLE 6.
DSA screening within the first two posttransplant decades.
| 20-year survivors | Total (n = 248) | Group 1 (n = 96) | Group 2 (n = 152) | ||||
|---|---|---|---|---|---|---|---|
| Excluded | 50 (20.2%) | 21 (21.9%) | 29 (19.1%) | ||||
| No Screening a | 36 (14.5%) | 15 (15.6%) | 21 (13.8%) | ||||
| unknown DSA-onset b | 14 (5.6%) | 6 (6.3%) | 8 (5.3%) | ||||
| 20-year survivors | Total (n = 198) | Group 1 (n = 75) | Group 2 (n = 123) | p-value | |||
| n | n | n | |||||
| Overall DSA | 198 | 39 (19.7%) | 75 | 11 (14.7%) | 123 | 28 (22.8%) | 0.228 |
| HLA-Class I | 15 (7.6%) | 3 (4.0%) | 17 (13.8%) | 0.029* | |||
| HLA-Class II | 29 (14.6%) | 8 (10.7%) | 26 (21.1%) | 0.079 | |||
| Number of DSA c | 198 | 0 (0–6) | 75 | 0 (0–2) | 123 | 0 (0–6) | 0.119 |
| Number of DSA d | 39 | 1 (1–6) | 11 | 1 (1–2) | 28 | 1 (1–6) | 0.062 |
| 0 | 198 | 159 (80.3%) | 75 | 64 (85.3%) | 123 | 95 (77.2%) | |
| 1 | 198 | 27 (13.6%) | 75 | 10 (13.3%) | 123 | 17 (13.8%) | |
| 2 | 198 | 8 (4.0%) | 75 | 1 (1.3%) | 123 | 7 (5.7%) | |
| 3 | 198 | 1 (0.5%) | 75 | 0 (0.0%) | 123 | 1 (0.8%) | |
| 4 | 198 | 2 (1.0%) | 75 | 0 (0.0%) | 123 | 2 (1.6%) | |
| 6 | 198 | 1 (0.5%) | 75 | 0 (0.0%) | 123 | 1 (0.8%) | 0.512 |
| Number of DSA Class I c | 198 | 0 (0–3) | 75 | 0 (0–1) | 123 | 0 (0–3) | 0.130 |
| Number of DSA Class I d | 39 | 0 (0–3) | 11 | 0 (0–1) | 28 | 0 (0–3) | 0.278 |
| 0 | 198 | 183 (92.4%) | 75 | 72 (96.0%) | 123 | 111 (90.2%) | |
| 1 | 198 | 11 (5.6%) | 75 | 3 (4.0%) | 123 | 8 (6.5%) | |
| 2 | 198 | 2 (1.0%) | 75 | 0 (0.0%) | 123 | 2 (1.6%) | |
| 3 | 198 | 2 (1.0%) | 75 | 0 (0.0%) | 123 | 2 (1.6%) | 0.542 |
| Number of DSA Class II c | 198 | 0 (0–3) | 75 | 0 (0–2) | 123 | 0 (0–3) | 0.191 |
| Number of DSA Class II d | 39 | 1 (0–3) | 11 | 1 (0–2) | 28 | 1 (0–3) | 0.449 |
| 0 | 198 | 169 (85.4%) | 75 | 67 (89.3%) | 123 | 102 (82.9%) | |
| 1 | 198 | 21 (10.6%) | 75 | 7 (9.3%) | 123 | 14 (11.4%) | |
| 2 | 198 | 6 (3.0%) | 75 | 1 (1.3%) | 123 | 5 (4.1%) | |
| 3 | 198 | 2 (1.0%) | 75 | 0 (0.0%) | 123 | 2 (1.6%) | 0.544 |
| MFI e | |||||||
| Max MFI all DSA | 39 | 5202 (552 21′896) | 11 | 5840 (552–17′203) | 28 | 4765 (681–21′896) | 0.618 |
| Max MFI DSA Class I | 15 | 1,146 (552–7,577) | 3 | 653 (552–7,577) | 12 | 1,175 (720–6,278) | 0.448 |
| Max MFI DSA Class II | 29 | 6,605 (502–21′896) | 8 | 6,851 (558–17′203) | 21 | 6,605 (502–21′896) | 0.981 |
| PIRCHE-II scores | |||||||
| Total PIRCHE-II score (A, B, DR) | 39 | 42.61 (10.00–111.63) | 11 | 40.80 (14.07–97.72) | 28 | 42.79 (10.00–111.63) | 0.852 |
| PIRCHE-II score (A, B) | 39 | 29.69 (2.07–85.74) | 11 | 30.99 (4.31–79.97) | 28 | 28.85 (2.07–85.74) | 0.311 |
| PIRCHE-II score (DR) | 39 | 11.27 (0–28.70) | 11 | 11.00 (0–28.70) | 28 | 13.43 (0–58.58) | 0.598 |
| DSA-onset (months) f | 39 | 211 (0–250) | 11 | 213 (0–250) | 28 | 208 (148–249) | 0.492 |
a
No HLA-antibody screening during the observation period.
b
First HLA-antibody screening performed beyond 21 years posttransplant and DSA-positive.
c
All KTRs.
d
DSA-positive KTRs only.
e
MFI, mean fluorescence intensity. Highest value measured up to 21 years posttransplant.
f
Time from transplantation to first DSA-detection in months.